Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02985554 |
|
Recruitment Status :
Terminated
(Study stopped early due to slow accrual and safety concerns.)
First Posted : December 7, 2016
Last Update Posted : June 25, 2020
|
Sponsor:
University of Chicago
Information provided by (Responsible Party):
University of Chicago
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | February 6, 2019 |
| Actual Study Completion Date : | June 22, 2020 |